지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Objective : Rhus verniciflua Stokes (RVS) has anticancer effect confirmed by preclinical studies and historical records. We thus tried to evaluate retrospectively the effect of RVS as a complementary medicine for patients with advanced non-small-cell lung cancer (NSCLC) showing refractory to conventional chemotherapy.
Patients and Methods : From June 1, 2006 to June 30, 2007, patients with advanced NSCLC who received both the standardized RVS extract and a standard course of second or more line therapy such as pemetrexed (Alimta<SUP>®</SUP>), erlotinib (Tarceva<SUP>®</SUP>), and gefitinib (Iressa<SUP>®</SUP>) were checked. A total of 13 patients were eligible for the final analysis after fulfilling inclusion/exclusion criteria. Time to progression (TTP) of these patients treated with the standardized RVS extract was checked in the aftercare period.
Results : Patients received RVS treatment for a median period of 296 (range 84-698) days. The median TTP was 220.5 (range 36-489) days, and three patients (23.1%) had TTP values of 15 more months. No significant side effects from RVS treatment have been observed.
Conclusion : The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents, since it prolonged TTP without significant adverse effects. This study suggests that the standardized RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. Further clinical trials and preclinical studies are necessary to determine the efficacy and safety of the standardized RVS extract in NSCLC.
Patients and Methods : From June 1, 2006 to June 30, 2007, patients with advanced NSCLC who received both the standardized RVS extract and a standard course of second or more line therapy such as pemetrexed (Alimta<SUP>®</SUP>), erlotinib (Tarceva<SUP>®</SUP>), and gefitinib (Iressa<SUP>®</SUP>) were checked. A total of 13 patients were eligible for the final analysis after fulfilling inclusion/exclusion criteria. Time to progression (TTP) of these patients treated with the standardized RVS extract was checked in the aftercare period.
Results : Patients received RVS treatment for a median period of 296 (range 84-698) days. The median TTP was 220.5 (range 36-489) days, and three patients (23.1%) had TTP values of 15 more months. No significant side effects from RVS treatment have been observed.
Conclusion : The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents, since it prolonged TTP without significant adverse effects. This study suggests that the standardized RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. Further clinical trials and preclinical studies are necessary to determine the efficacy and safety of the standardized RVS extract in NSCLC.
목차
Introduction
Patients and Methods
Results
Discussion
Acknowledgement
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
옻나무 열수추출물에 의한 운동수행능력향상에 미치는 효과 및 기전 연구
약학회지
2014 .01
-
Effects of Rhus Verniciflua Stokes (RVS) on the Plasma Level of Cholesterol and Tumor Growth in Mouse
Toxicological Research
1999 .06
-
건칠의 항주름 효과와 미백효과 연구
한방안이비인후피부과학회지
2016 .01
-
참옻 추출물의 MCF-7 인체 유방암 세포에서 증식 억제효과
대한한의학방제학회지
2016 .01
-
Evaluation of Genotoxicity of Water and Ethanol Extracts from Rhus verniciflua Stokes (RVS)
Toxicological Research
2008 .06
-
Carcinostatic effect of allergen removed Rhus Verniciflua stokes based Traditional Korean Medicine on a patient with lung adenocarcinoma; single case report
Oriental pharmacy and experimental medicine
2008 .01
-
알러젠 제거 옻나무 추출물 투여로 삶의 질 개선과 생존기간 연장을 보인 비소세포성 폐암 환자 1례
대한암한의학회지
2008 .01
-
알러젠 제거 옻나무 추출물을 투여한 고령의 진행성 비소세포폐암 환자 1례
대한암한의학회지
2010 .01
-
Effects of Rhus verniciflua Stokes ( RVS ) on Cell-associated Detoxificant Enzymes and Glucose Oxidase-mediated Toxicity in Cultured Mouse Hepatocytes
Toxicological Research
2000 .06
-
Study on the Inhibition of Whole Blood Platelet-Aggregation and antioxidative effects from Rhus verniciflua Stokes
대한약학회 학술대회
2002 .01
-
알러젠 제거 옻나무 추출물 단독치료로 생존기간 연장 및 삶의 질 개선을 보인 진행성 비소세포폐암 환자 1례
대한암한의학회지
2012 .01
-
漆皮 추출물의 담도암 세포주 SNU-1079와 SNU-1196에 대한 항암효과
대한한방내과학회지
2015 .01
-
Study on the Inhibition of anti-platelet and Anticoagulant activity from Rhus verniciflua Stokes
대한약학회 학술대회
2003 .01
-
Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2012 .01
-
Gene expression profiling in the human keratinocyte cell line, HaCaT exposed to urushiol isolated from sap of Korean lacquer tree (Rhus verniciflua Stokes)
Molecular & cellular toxicology
2010 .01
-
Right ventricular failure in congenital heart disease
Clinical and Experimental Pediatrics
2013 .01
-
전이성 유두상 갑상선암 환자를 대상으로 투여한 알러젠 제거 옻나무 추출물의 종양 소퇴 1례
대한한방내과학회지
2008 .01
-
Rhinovirus 유발성 기도염증반응에서 Interleukin-8과 전사인자 NF(nuclear factor)-κB의 역할에 대한 연구
Tuberculosis and Respiratory Diseases
2003 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-519-000282247